Benzyl Benzoate

證據等級: L5

預測適應症: 0 個

Benzyl Benzoate: Drug Repurposing Evaluation Report

One-Sentence Summary

Benzyl Benzoate (DrugBank: DB00676) is a marketed drug in Malaysia with 6 registered licenses. However, the TxGNN model has not generated any predicted new indications for this compound, and critical data gaps remain in mechanism of action and safety information, preventing further repurposing evaluation at this time.

Quick Overview

Item	Content
Drug Name (INN)	Benzyl Benzoate
DrugBank ID	DB00676
Original Indication	Not available in current dataset
Predicted New Indication	None — no TxGNN predictions generated
TxGNN Prediction Score	N/A
Evidence Level	N/A — no prediction to evaluate
Malaysia Market Status	✓ Marketed
Number of Registrations	6
Recommended Decision	Hold

Why Are There No Predictions?

Benzyl Benzoate is a well-established topical antiparasitic and scabicidal agent. The TxGNN model did not generate any repurposing candidates for this drug. Several factors may contribute to this outcome:

Incomplete drug characterisation: The mechanism of action (MOA) data is currently unavailable in the evidence pack. Without MOA information, the model’s ability to identify mechanistically plausible new indications may be limited.
Nature of the drug: Benzyl Benzoate is primarily used as a topical agent (for scabies and pediculosis). Drugs with predominantly local/topical mechanisms may have fewer systemic target interactions in the knowledge graph, resulting in fewer or no repurposing candidates being identified.
Sparse knowledge graph connectivity: If the drug node in the TxGNN knowledge graph has limited edges (few known drug–target, drug–disease, or drug–pathway connections), the prediction algorithm may not have sufficient signal to generate confident repurposing hypotheses.

Clinical Trial Evidence

Currently no predicted indications to evaluate — no clinical trial search was performed.

Literature Evidence

Currently no predicted indications to evaluate — no literature search was performed.

Malaysia Market Information

6 licenses are registered in Malaysia. However, detailed license information (authorization numbers, product names, dosage forms, and approved indications) was not available in the current dataset.

Note: License details should be retrieved from the NPRA database to complete this section.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

Data Gaps Summary

The following critical data gaps were identified and must be resolved before any repurposing evaluation can proceed:

ID	Item	Severity	Impact	Remediation
DG001	Package insert warnings / contraindications	Blocking	Cannot enter Stage 1 safety screening	Download and parse package insert PDF from regulatory authority website
DG002	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model did not generate any repurposing predictions for Benzyl Benzoate. Combined with the absence of MOA data and safety information, there is insufficient basis to advance this candidate into further evaluation.

To proceed, the following is needed:

Resolve DG001 (Blocking): Obtain package insert warnings and contraindications from the regulatory authority
Resolve DG002 (High): Retrieve mechanism of action data from DrugBank
Populate Malaysia license details (authorization numbers, product names, dosage forms, approved indications) from the NPRA database
Re-run TxGNN prediction pipeline after enriching the drug’s knowledge graph node with MOA and indication data
If predictions remain absent after data enrichment, consider whether the drug’s topical/local action profile inherently limits systemic repurposing potential
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.